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Aim: The aim of the study was to estimate the dose at the reference point applying an
aSi-EPID device in the course of patient treatment.
Materials and methods: The method assumes direct proportionality between EPID signal and
dose delivered to the patient reference point during the treatment session. The procedure
consists of treatment plan calculation for the actual patient in the arc technique. The plan
was realized with an elliptic water-equivalent phantom. An ionization chamber inside the
phantom measured the dose delivered to the reference point. Simultaneously, the EPID
matrix measured the CU distribution. EPID signal was also registered during patient irra-
diation with the same treatment plan. The formula for in vivo dose calculation was based
on the CU(g) function, EPID signal registered during therapy and the relation between the
dose and EPID signal level measured for the phantom. In vivo dose was compared with dose
planned with the treatment planning system.
Irradiation was performed with a Clinac accelerator by Varian Medical Systems in the
RapidArc technique. The Clinac was equipped with an EPID matrix (electronic portal image
device) of aSi-1000. Treatment plans were calculated with the Eclipse/Helios system. The
phantom was a Scanditronix/Wellhöfer Slab phantom, and the ionization chamber was a
0.6 ccm PTW chamber.
Results: In vivo dose calculations were performed for ﬁve patients. Planned dose at thereference point was 2Gy for each treatment plan. Mean in vivo dose was in the range of
1.96–2.09.
Conclusions: Our method was shown to be appropriate for in vivo dose evaluation in the
RapidArc technique.
ie Ce© 2009 Wielkopolsk
1. IntroductionVeriﬁcation of dynamic methods in radiotherapy (RT) is a crit-
ical step in medical physicist practice. Despite many available
methods, dose veriﬁcation in dynamic techniques presents a
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challenge to the quality assurance team.
The present range of veriﬁcation methods in intensity
modulated radiotherapy (IMRT) allows one to perform pre-
treatment dose control rather than in vivo dosimetry.101, Poland. Tel.: +48 32 278 80 18; fax: +48 32 278 80 71.
The methods individually are insufﬁcient to assure accu-
rate dose delivery veriﬁcation.1
Traditional treatment veriﬁcation can be done by single-
point measurement in a phantom. Additionally, dose
Published by Elsevier Urban & Partner Sp. z.o.o. All rights reserved.
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preports of practical oncology a
istribution control can be accomplished by testing of agree-
ent between calculated and measured dose distribution in
orresponding planes. For this purpose largely utilized are
morphous silicon electronic portal imaging devices (aSi-
PID).2–9
Although acquisition of a ﬂuence map itself does not pro-
ide absolute dose measurements, it is capable of providing
elative dose measurement. Correlation of the portal dosime-
ry and ion chamber dosimetry enables precise determination
f the dose. For in vivo dosimetry purposes, dosimetric prop-
rties of EPID and point dose measurement worked together
re used. Namely, the image from the EPID can be converted
nto the absolute dose.10
Characteristics of aSi-EPID and its usefulness for IMRT
osimetric purposes have been quite extensively discussed.
inearity of dose response, ﬁeld size dependence and inde-
endence on beam energy have been proven.3–7,9,11,12
A novel solution of dose delivery is offered in the Rapi-
Arc technique. It is an extension of IMRT, where the dose
s optimized during inverse planning and then realized in a
ingle dynamically modulated arc. While the gantry is rotat-
ng, MLC leaves are moved, modulating dose distribution
ontinuously.10,13 This new modality demands a reliable form
f veriﬁcation process. Therefore substantial questions are:
s RapidArc a safe delivery method, and what approach is
equired for RapidArc IMRT delivery veriﬁcation?
According to the preliminary reports RapidArc is an appro-
riate technique in some tumour locations and increases
exibility in generating highly conformal treatment. Reducing
he overall treatment time, increased conformity and organs
t risk (OARs) sparing are mostly emphasized.14–19 The ﬁrst
eports on dose veriﬁcation indicate auspicious abilities of
ortal dosimetry conducted for RapidArc ﬁelds.10,13
In this paper the authors have tried to demonstrate the
sefulness of aSi-EPID for RapidArc dosimetric veriﬁcation.
The signal detected by EPID is expressed in calibrationunits
CU).4,12,20 First, the relation between the signal and the dose
elivered from the photon beam was measured. The signal
as registered with the presence of an absorbent (layers of
he phantom). The number of CU was described as a function
f the absorbent thickness, located between the source and
he EPID cassette. These data were then used for assessment
f the dose absorbed in patient tissues. In order to do that,
n assumption was made that there is proportionality of the
PID signal measured during the treatment session and the
ose absorbed in the patient’s body.
Plans calculated for the patients are transferred to the
hantom shape and realized in accordance with calculated
eometry. During the gantry rotation the EPID signal is
cquired and the absolute dose at the reference point in the
hantom ismeasured using the ion chamber. Then the patient
s irradiated with EPID signal acquisition simultaneously. The
oncept of dose determination in the patient is based on the
ollowing issues that need to be considered: (i) the dependence
etween EPID signal and absorbing layers’ thickness, (ii) the
elationship between dose measured by the ion chamber in
he phantom and EPID signal, and ﬁnally (iii) EPID signal mea-
ured during patient treatment session. These three elements
llow one to carry out in vivo dosimetry with the help of a
ortal cassette.diotherapy 1 5 ( 2 0 1 0 ) 8–14 9
The aim of the study was to estimate the dose at the refer-
ence point (in the patient’s body) applying the aSi-EPID device
in the course of patient treatment with the RapidArc tech-
nique.
2. Materials and methods
Our method enables us to perform in vivo dosimetry in the
RapidArc radiotherapy technique. In general, in vivo dosime-
try in teleradiotherapy is performed indirectly, with detectors
located on the body surface. In our study an EPID cassette was
used to evaluate the dose delivered to a speciﬁc point located
in the patient’s body (reference point) during arc therapy. The
experiment of in vivo dose evaluation was performed in three
steps. First, the dosimetric characteristic of the EPID detec-
tors was estimated; then, the relation between the absolute
dose measured with the ion chamber in a water-equivalent
phantom and EPID signal registered during phantom irradia-
tion was evaluated; and ﬁnally, the EPID signal was measured
during an actual radiotherapy session. The analysis of the
measured quantities led to the formula for calculation of the
in vivo dose delivered during treatment.
2.1. EPID dosimetry—basic assumptions
In this part of the experiment we tested the linear relation
between treatment time, dose at the reference point and EPID
signal. We also measured the EPID signal’s dependence on the
thickness of absorbent located between the source and the
detector’s matrix.
In our experiment we assumed that the dose at point P (the
reference point) located inside the patient’s body is directly
proportional to the number of monitor units (MU) and calibra-
tion units (CU—the level of the EPID signal) (Fig. 1).
This assumption is valid only for a homogeneous density
of the irradiated volume. The patient’s body consists of differ-
ent tissue types of varied density. However, assuming that the
gantry and EPID cassette make a 360-degree turn on the accel-
erator axis we may approximate that density of the patient’s
body is homogeneous. The in vivo dosimetry method reported
in this paper can be applied under the condition that the treat-
ment plan is realized in one 360-degree turn. During the entire
gantry rotation eachpoint in thepatient is locatedbetween the
EPID and the reference point (Fig. 2).
In vivo dosimetry and dose calculations with the portal
cassette require knowledge of the dosimetric characteristics
of the EPID detectors. Therefore, the actual experiment was
preceded with measurement of the EPID signal as a function
of MU and irradiation ﬁeld size. EPID signal was found to be
directly proportional to MU number for different ﬁeld sizes
and for different photon energies.12 The graph shown in Fig. 1
presents the linear relation between MU and CU.
2.2. EPID signal dependence on the absorbent
thicknessThe EPID signal depends on the monitor unit and is also cor-
related with the radiation absorption in the patient’s body.
To apply the EPID for in vivo dosimetry we need to test the
10 reports of practical oncology and radiotherapy 1 5 ( 2 0 1 0 ) 8–14
Fig. 1 – Absolute dose delivered to the reference point (P) located inside the treated volume is directly proportional to the
number of monitor units (MU). The reference point coincides with the isocentre point. Direct proportionality was found
ies and ﬁeld sizes (graph in the upper-right corner). Then, for a
ID signal is considered to be proportional to the dose at point P.between EPID response (CU level) and MU for different energ
homogeneous density, single beam and static technique, EP
dependence of EPID signal on thickness of the absorbingmate-
rial.
Layers of the phantom plates were placed on the therapeu-
tic table perpendicularly to the beamaxis. Source axis distance
irradiation technique (SAD) was used in this experiment. CU
values were measured while number of MU, ﬁeld size and dis-
tance (f) between the lowest surface of the absorbent and the
EPID were constant during the experiment (Fig. 3). The lay-
Fig. 2 – In the static technique the in vivo dose in A differs
from the dose in B even though the same treatment time
was applied. Inhomogeneities of the density inside the
irradiated volume inﬂuence the EPID response. In A and B
structures of different densities (2 and 3) are located
behind and in front of point P, which alters the correlation
between MU, in vivo dose and CU values. In the arc
technique, both A and B situations are included in the
360-degree turn. Rotation on the accelerator axis averages
the inhomogeneities inside the volume and retains the
correlation between MU, P dose and EPID response.
Fig. 3 – Thickness of the absorbing material located
between the source and EPID cassette inﬂuences the signal
level of EPID. Signal level decreases when increasing the
absorbent thickness. To evaluate the CU dependence on the
absorbent thickness (g) we measured the EPID signal for g
values ranging from 0 to 18 cm. An amorphous silicon
portal imaging device (aSi-EPID) of type aS1000 was
applied. Single beam of 6MV photon energy and constant
number of MU equal to 200 were applied. Field size was
10 cm×10 cm. Distance between EPID cassette and the
source (f) was 140 cm. f1 was constant in this part of the
experiment and equal to 40 cm.ers ranged in thickness from 0 to 18 cm with an increment of
1 cm. All measurements were performed with a photon beam
of 6MVandwith aS1000operating in “integrated image”mode.
This mode continuously acquires an image over the entire
time of beam delivery.
CU(g) exponential function (Eq. (1)), derived from the exper-
imental values, was found to describe the detector response
reports of practical oncology and radiotherapy 1 5 ( 2 0 1 0 ) 8–14 11
Fig. 4 – Exponential function CU(g) =  · exp(−ı · g) expresses the dependence of EPID signal on absorbent thickness.
Coefﬁcient  represents the CU(g) dependence on MU and ı represents the CU(g) dependence on the distance between the
lowest surface of the phantom and the EPID matrix (f1). In this experiment  and ı are equal to 1.15 and 0.05 respectively
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epending on absorption in the material (Fig. 4).
U(g) = 1.1471 · exp(−0.0521 · gavg) (1)
.3. Absolute dose measurement vs. EPID signal
o evaluate the in vivo dose based on the EPID signal regis-
ered for the actual treatment planweneed to ﬁnd the relation
etween this quantity and between the dose measured in the
ater phantomand the EPID signal registeredduringphantom
rradiation.
In this part of the experiment the treatment plan of
he prostate case was applied to irradiate the elliptic slab
hantom (which was a water-equivalent phantom) in order
o compare the EPID response with the dose measured
ith the ion chamber located at the reference point of the
hantom.
Actual treatment plan was calculated with the Eclipse/
elios (Varian) treatment planning system (TPS) for linear
ccelerator Clinac 23EX Shilette (Varian) using the dynamic
apidArc technique. This TPS worked with an AAA algorithm.
he grid of computation was set to 0.25 cm. The plan was
ptimized for a 6MV photon beam. The treatment plan was
hen recalculated according to the phantom geometry, con-
idering homogeneous density of the phantom volume. The
ose measured at the phantom reference point (P1m) differed
rom the dose calculated for the patient’s anatomy, while
he speciﬁc features of the plan, i.e. gantry start and stop
ngle, gantry and leaves speed, leaves’ positions, dose rate
nd MU were retained. EPID signal (CU1m) and dose at the
hantomreferencepoint (P1m)weremeasured simultaneously
uring phantom irradiation (Fig. 5). Those quantities were
sed for further calculations of the in vivo dose delivered dur-
ng patient therapy.t geometry of the phantom in respect to the EPID matrix
2.4. EPID in vivo dosimetry—formula for in vivo dose
calculation
This part of the experiment assumed calculation of the abso-
lute in vivo dose at the reference point delivered during
therapy for the actual patient. Five patients were randomly
selected for the experiment. The dose distribution for each
patient was computed in TPS so that the planned dose at the
reference point for each patient was 2Gy. Planned dose and
calculated one were compared. All statistics and graphs were
performed in Excel—Ofﬁce application.
During radiotherapy the EPID matrix registered an integral
signal (CU2m). Treatment time was identical with the irra-
diation time during phantom measurement and the same
treatment parameters were applied (Fig. 5).
The relationship between in vivo dose (P2c) and dose mea-
sured with the ion chamber during phantom irradiation (P1m)
can be expressed by the formula:
P2c · B = P1m · A (2)
where A and B were deﬁned as CU ratios:
A = CU1c
CU1m
and B = CU2c
CU2m
;
CU1c and CU2c were the EPID responses derived from the
CU(g) formula developed in the ﬁrst part of this paper. In the
TPS, average equivalent thicknesses (gavg) were calculated for
both the elliptic phantom and for the patient’s body. Calcu-
lated g values were introduced to the CU(g) equation. The
resultant CU values (CU1c and CU2c) describe the level of radi-
ation absorption in the phantom and in the patient’s body for
constant treatment time.
12 reports of practical oncology and radiotherapy 1 5 ( 2 0 1 0 ) 8–14
Fig. 5 – (A) The appropriate elliptic slab phantom (Scanditronix Wellhöfer I’mRT Phantom) and 0.6 ccm PTW ion chamber
(Scanditronix Wellhöfer) were used for measurements. The ion chamber located at point P registered the absolute dose
during irradiation (P1m). At the same time the detector’s matrix measured the EPID signal (CU1m). The image was acquired
at source—EPID distance (f) at 140 cm in the “integrated image” mode. f1 varies with the gantry angle and depends on the
phantom geometry. For the phantom volume gavg deﬁned as the mean distance between point P and the phantom surface
was calculated. (B) EPID signal (CU2m) registered during the treatment session was used for evaluation of the in vivo dose
(P2c) delivered to the patient reference point. Average equivalent thickness (gavg-eqv) of the patient’s body was computed for
e anCU2c calculations. During gantry rotation f1 changes its valu
Additionally, calculated CU values normalized the mea-
sured CU in respect to the constant geometry of irradiation.
In this part of the experiment the distance between the
EPID and the external surface of both phantom and patient
varies with the gantry angle and depends on the shape of
the irradiated volume. It inﬂuences the EPID response. For
this reason coefﬁcients A and B were introduced to the P2c
formula.
We may conclude that both coefﬁcients express different
conditions in both parts of the experiment. Finally, dose at the
referencepoint for thepatient during therapy canbe evaluated
with the formula:
P2c = P1m × (CU1c × CU2m)(CU2c × CU1m)
[Gy] (3)
where P2c is the dose value delivered to the reference point
during patient therapy, CU2m is the EPID signal measured
during patient irradiation while CU2c is the EPID signal calcu-
lated based on CU(g) function for average patient’s thickness.
P1m is the absolute dose measured in the water-equivalent
phantom. CU1m is the EPID signal registered during phan-
tom irradiation and CU1c is the calculated EPID response
based on the CU(g) function and average thickness of the
phantom.d modiﬁes the EPID response.
3. Results
In this study, we tested a new in vivo dosimetry method in the
dynamic arc technique for measurement of the dose delivered
to the reference patient point. We applied our method to com-
pare the dose planned in TPS with the actual dose measured
during irradiation.
Dose measured in a water-equivalent phantom and CU val-
ues registered during therapy and during phantom irradiation
were used for P2c calculations. All those values calculated
for each patient are shown in Table 1. Absolute difference
between planed dose and calculated P2c was not higher than
0.09Gy.
4. Discussion
A signiﬁcant advantage of this work is the determination of
the new in vivo dosimetry tool for the quality assurance pro-
cedure in the dynamic radiotherapy technique. This method
providesmeasurable beneﬁts following from in vivo dosimetry
performed during the course of radiotherapy.
The formula for evaluation of the dose delivered dur-
ing irradiation (P2c) was based on the dose measured in a
water-equivalent phantom with an ion chamber and signal
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registered during irradiationwith an EPID cassette,which is an
integral part of the radiotherapy device. Data analysis showed
that the difference between the dose calculated at the refer-
ence point and planned in the TPS is insigniﬁcant in respect
to the accuracy of the measurement.
We believe that the presented method has the potential
to provide an analytic tool in the quantitative evaluation of
radiotherapy in the dynamic arc technique.
5. Conclusion
In vivo dosimetry in the dynamic radiotherapy technique
allows dose evaluation delivered to the patient during ther-
apy. The presented method increases the quality and safety
of radiotherapy by controlling the correct operation of the
treatment devices and dose delivered during each treatment
session.
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